Guangxi Wuzhou Zhongheng Group Full Year 2024 Earnings: CN¥0.11 loss per share (vs CN¥0.025 profit in FY 2023)
Guangxi Wuzhou Zhongheng Group (SHSE:600252) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥2.27b (down 27% from FY 2023).
- Net loss: CN¥377.0m (down from CN¥84.3m profit in FY 2023).
- CN¥0.11 loss per share (down from CN¥0.025 profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Guangxi Wuzhou Zhongheng Group's share price is broadly unchanged from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Guangxi Wuzhou Zhongheng Group you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:600252
Guangxi Wuzhou Zhongheng Group
Researches, develops, manufactures, and sells pharmaceuticals in China.
Good value with adequate balance sheet.
Market Insights
Community Narratives
